Brainstorm Cell Therapeutics | BCLI - Selling And Administration Expenses


Brainstorm Cell Therapeutics reported $1.39M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
Brainstorm Cell Therapeutics USD 1.39M 326K Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.21M 120K Dec/2025
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 104.9M 13.17M Mar/2026
Gilead Sciences USD 1.45B 326M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 46.29M 18.35M Mar/2026
Mesoblast USD 28.54M 9.69M Dec/2025